Lexicon Pharmaceuticals, Inc. (LXRX)

$1.21

+0.04

(+3.42%)▲

Market is closed - opens 7 PM, 28 Sep 2023

Insights on Lexicon Pharmaceuticals, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 24.0K → 317.0K (in $), with an average increase of 92.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -23.38M → -44.90M (in $), with an average decrease of 25.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 84.6% return, outperforming this stock by 137.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 165.1% return, outperforming this stock by 187.5%

Performance

  • $1.17
    $1.26
    $1.21
    downward going graph

    3.31%

    Downside

    Day's Volatility :7.14%

    Upside

    3.96%

    downward going graph
  • $1.04
    $3.79
    $1.21
    downward going graph

    14.05%

    Downside

    52 Weeks Volatility :72.56%

    Upside

    68.07%

    downward going graph

Returns

PeriodLexicon Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-46.22%
-1.1%
0.0%
6 Months
-47.84%
1.6%
0.9%
1 Year
-51.65%
4.2%
3.1%
3 Years
-25.0%
24.2%
17.1%

Highlights

Market Capitalization
296.4M
Book Value
$0.76
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.76
PEG Ratio
-0.14
Wall Street Target Price
5.55
Profit Margin
0.0%
Operating Margin TTM
-31635.14%
Return On Assets TTM
-37.51%
Return On Equity TTM
-101.65%
Revenue TTM
407.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
805.7%
Gross Profit TTM
-52.7M
EBITDA
-128.3M
Diluted Eps TTM
-0.76
Quarterly Earnings Growth YOY
-0.63
EPS Estimate Current Year
-0.81
EPS Estimate Next Year
-0.76
EPS Estimate Current Quarter
-0.17
EPS Estimate Next Quarter
-0.17

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Lexicon Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 358.68%

Current $1.21
Target $5.55

Company Financials

FY17Y/Y Change
Revenue
90.3M
↑ 8.4%
Net Income
-129.1M
↓ 8.75%
Net Profit Margin
-142.86%
↑ 26.85%
FY18Y/Y Change
Revenue
63.2M
↓ 30.03%
Net Income
-120.5M
↓ 6.59%
Net Profit Margin
-190.71%
↓ 47.85%
FY19Y/Y Change
Revenue
322.1M
↑ 409.54%
Net Income
130.1M
↓ 207.95%
Net Profit Margin
40.4%
↑ 231.11%
FY20Y/Y Change
Revenue
24.0M
↓ 92.55%
Net Income
-58.6M
↓ 145.01%
Net Profit Margin
-244.11%
↓ 284.51%
FY21Y/Y Change
Revenue
298.0K
↓ 98.76%
Net Income
-87.8M
↑ 49.82%
Net Profit Margin
-29.4K%
↓ 29204.88%
FY22Y/Y Change
Revenue
139.0K
↓ 53.36%
Net Income
-101.9M
↑ 16.16%
Net Profit Margin
-73.3K%
↓ 43892.02%
Q1 FY22Q/Q Change
Revenue
37.0K
↑ 164.29%
Net Income
-23.5M
↓ 8.34%
Net Profit Margin
-63.4K%
↑ 119487.06%
Q2 FY22Q/Q Change
Revenue
35.0K
↓ 5.41%
Net Income
-24.6M
↑ 4.73%
Net Profit Margin
-70.2K%
↓ 6799.92%
Q3 FY22Q/Q Change
Revenue
39.0K
↑ 11.43%
Net Income
-23.4M
↓ 4.88%
Net Profit Margin
-60.0K%
↑ 10281.9%
Q4 FY22Q/Q Change
Revenue
67.0K
↑ 71.79%
Net Income
-30.5M
↑ 30.39%
Net Profit Margin
-45.5K%
↑ 14453.24%
Q1 FY23Q/Q Change
Revenue
24.0K
↓ 64.18%
Net Income
-30.9M
↑ 1.35%
Net Profit Margin
-128.8K%
↓ 83257.4%
Q2 FY23Q/Q Change
Revenue
317.0K
↑ 1220.83%
Net Income
-44.9M
↑ 45.3%
Net Profit Margin
-14.2K%
↑ 114605.53%
FY17Y/Y Change
Total Assets
436.5M
↓ 8.22%
Total Liabilities
384.4M
↑ 20.81%
FY18Y/Y Change
Total Assets
284.1M
↓ 34.91%
Total Liabilities
310.5M
↓ 19.22%
FY19Y/Y Change
Total Assets
417.7M
↑ 47.01%
Total Liabilities
300.6M
↓ 3.2%
FY20Y/Y Change
Total Assets
203.8M
↓ 51.21%
Total Liabilities
47.4M
↓ 84.23%
FY21Y/Y Change
Total Assets
136.9M
↓ 32.82%
Total Liabilities
23.3M
↓ 50.83%
FY22Y/Y Change
Total Assets
194.3M
↑ 41.92%
Total Liabilities
77.2M
↑ 231.02%
Q1 FY22Q/Q Change
Total Assets
136.2M
↓ 0.53%
Total Liabilities
43.5M
↑ 86.5%
Q2 FY22Q/Q Change
Total Assets
112.3M
↓ 17.52%
Total Liabilities
41.5M
↓ 4.57%
Q3 FY22Q/Q Change
Total Assets
191.7M
↑ 70.65%
Total Liabilities
47.7M
↑ 14.87%
Q4 FY22Q/Q Change
Total Assets
194.3M
↑ 1.36%
Total Liabilities
77.2M
↑ 61.9%
Q1 FY23Q/Q Change
Total Assets
162.7M
↓ 16.25%
Total Liabilities
74.7M
↓ 3.25%
Q2 FY23Q/Q Change
Total Assets
316.7M
↑ 94.65%
Total Liabilities
130.4M
↑ 74.59%
FY17Y/Y Change
Operating Cash Flow
-185.4M
↑ 5.56%
Investing Cash Flow
50.5M
↑ 176.8%
Financing Cash Flow
149.9M
↑ 15090.78%
FY18Y/Y Change
Operating Cash Flow
-148.6M
↓ 19.84%
Investing Cash Flow
169.6M
↑ 235.65%
Financing Cash Flow
-2.2M
↓ 101.5%
FY19Y/Y Change
Operating Cash Flow
113.8M
↓ 176.58%
Investing Cash Flow
-155.9M
↓ 191.91%
Financing Cash Flow
-2.2M
↓ 0.8%
FY20Y/Y Change
Operating Cash Flow
-143.0M
↓ 225.62%
Investing Cash Flow
380.8M
↓ 344.3%
Financing Cash Flow
-147.6M
↑ 6532.35%
FY21Y/Y Change
Operating Cash Flow
-87.0M
↓ 39.14%
Investing Cash Flow
2.1M
↓ 99.45%
Financing Cash Flow
22.7M
↓ 115.38%
FY22Y/Y Change
Operating Cash Flow
-88.9M
↑ 2.11%
Investing Cash Flow
-71.1M
↓ 3468.63%
Financing Cash Flow
142.2M
↑ 526.22%
Q1 FY22Q/Q Change
Operating Cash Flow
-23.4M
↑ 2.6%
Investing Cash Flow
-4.4M
↓ 172.31%
Financing Cash Flow
23.3M
↓ 305.67%
Q2 FY22Q/Q Change
Operating Cash Flow
-24.4M
↑ 4.27%
Investing Cash Flow
-13.6M
↑ 209.62%
Financing Cash Flow
94.0M
↑ 303.79%
Q3 FY22Q/Q Change
Operating Cash Flow
-19.4M
↓ 20.4%
Investing Cash Flow
-77.2M
↑ 465.62%
Financing Cash Flow
94.0M
↑ 0.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-21.6M
↑ 10.96%
Investing Cash Flow
24.2M
↓ 131.32%
Financing Cash Flow
24.9M
↓ 73.51%
Q2 FY23Q/Q Change
Operating Cash Flow
-38.1M
↑ 20.57%
Investing Cash Flow
-74.6M
-
Financing Cash Flow
189.0M
↓ 23036.29%

Technicals Summary

Sell

Neutral

Buy

Lexicon Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.
-34.59%
-47.84%
-51.65%
-25.0%
-89.17%
Moderna, Inc.
Moderna, Inc.
-13.8%
-33.86%
-19.73%
39.08%
427.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.18%
1.46%
18.0%
45.55%
106.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.09%
18.19%
91.43%
165.4%
285.43%
Seagen, Inc.
Seagen, Inc.
4.8%
8.3%
56.96%
13.46%
180.29%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.03%
14.01%
23.51%
31.36%
85.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.
NA
NA
-0.14
-0.81
-1.02
-0.38
0.0
0.76
Moderna, Inc.
Moderna, Inc.
35.31
35.31
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.73
21.73
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
42.99
42.99
2.03
1.65
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.12
27.12
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.
Buy
$286.6M
-89.17%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.4B
427.53%
35.31
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
106.02%
21.73
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$407.6B
285.43%
42.99
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$40.6B
180.29%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.8B
85.35%
27.12
35.4%

Institutional Holdings

  • Artal Group S A

    48.00%

  • Bvf Inc

    8.16%

  • FMR Inc

    3.48%

  • Vanguard Group Inc

    2.64%

  • BlackRock Inc

    2.60%

  • JPMorgan Chase & Co

    1.20%

Corporate Announcements

  • Lexicon Pharmaceuticals, Inc. Earnings

    Lexicon Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio

Organization
Lexicon Pharmaceuticals, Inc.
Employees
135
CEO
Mr. Lonnel Coats
Industry
Health Technology

Discover More

FAQs